United States-based Dragonfly Therapeutics Inc has expanded its collaboration with Bristol Myers Squibb, a United States-based pharmaceutical company, to discover and produce Dragonfly's immunotherapies for multiple sclerosis and neuro-inflammation targets, it was reported on Monday.
According to the contract, Dragonfly is to offer Bristol Myers Squibb the option to license global intellectual property rights to multiple candidates produced utilising Dragonfly's proprietary platform for multiple new targets.
The deal includes an upfront payment of USD55m to Dragonfly from Bristol Myers Squibb, while Dragonfly will be eligible to receive additional payments associated with development, regulatory and sales milestones and potential royalties on sales of approved products.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients